杨森制药的厄达替尼是靶向药物吗？

(Erdafitinib) is a targeted drug developed by Janssen Pharmaceuticals. From its founding, Janssen's mission has been research and development and innovation. Over the past half century, Janssen has introduced more than 80 new drugs to the world. Janssen develops many of the world's best-in-class prescription medicines across multiple therapeutic areas. These areas include the central nervous system, gastrointestinal system, pain control, and antifungal infection areas.

Targeted therapy is a new treatment model with accurate efficacy and good tolerability, and has achieved good results especially in the treatment of solid malignant tumors. Therefore, targeted inhibitors for advanced or metastatic urothelial cancer are currently one of the research hotspots in this field. After extensive preliminary research, the U.S. FDA finally granted accelerated approval on April 12, 2019, to the first targeted inhibitor Erdafitinib (trade name: Balversa) for the treatment of locally advanced and metastatic urothelial cancer in adult patients.

Erdafitinib is available as tablets in 3, 4 and 5 mg strengths. The recommended dose is 8 mg once daily. Before taking it, confirm whether there is any FGFR gene mutation in the tumor specimen. Assess serum phosphorus levels on days 14 to 21 after initial dose treatment. If serum phosphorus levels are <5.5 mg/dL and there are no eye diseases or grade 2 or above adverse reactions, increase the dose to 9 mg once daily. If vomiting occurs after taking this medicine, the next dose should be taken 1 day apart and should not be doubled.

The tablets may be swallowed whole with or without food. If vomiting occurs after taking the medicine, there is no need to take a supplementary dose and the next dose should be taken the next day. If you miss a dose, you can take it as soon as possible on the same day. Return to your normal daily dose the next day. Do not take double the dose (double the dose at one time) to make up for a missed dose. Treatment should be continued until disease progression or unacceptable toxicity occurs.

Recommended hot articles: /newsDetail/96503.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.